Targeting CD19 universal chimeric antigen receptor T cells (UCART-19) in refractory/relapsed B-cell acute lymphoblastic leukemia and aggressive lymphoma

Category Primary study
Registry of TrialsChinese Clinical Trial Register
Year 2019
This article has no abstract
Epistemonikos ID: 50a32c0dc1e76870d87559df5ac04aade5411891
First added on: Apr 07, 2025